Slide 1: Q4 and FY 2017 Results
K Pharm Q4 and FY 2017 Results
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation contains forward-looking statements, including statements about our plans to develop and commercialize our product candidates, our planned clinical trials for our prodrug product candidates, the timing of and our ability to obtain
Slide 3: Q4 and FY 2017 Results Call Participants
Q4 and FY 2017 Results Call Participants + Travis Mickle, Ph.D. - President & Chief Executive Officer + R. LaDuane Clifton, CPA - Chief Financial Officer, Secretary & Treasurer + Dan Cohen, M.A.L.S.— EVP, Government & Public Relations
Slide 4: Financial Results
Q4 and FY 2017 Financial Results + Q4 2017 net loss of $10.6M, or $0.72 per basic and diluted share, vs. Q4 2016 net loss of $9.9M, or $0.68 per basic and diluted share + Net loss for Q4 2017 was primarily due to loss from operations of $8.2 million and net interest expense and other items of $1.7 m
Slide 5: Financial Results
Q4 and FY 2017 Financial Results + Loss from operations decreased to $33.4M in FY 2017, as compared to $37.5M in FY 2016, primarily driven by the non-recurrence in 2017 of severance expense of $3.0M anda reduction in G&A spending of $1.2M * Total cash of $48.6M as of 12/31/2017, a decrease of $7.0M
Slide 6: Recent Development and Regulatory Updates
Recent Development and Regulatory Updates + Announced FDA Approval of APADAZ™ for the Short-Term Management of Acute Pain + Initiated Pivotal Efficacy Trial of KP415 + Announced Positive Topline Results from KP415 PK Study in Children and Adolescents with ADHD + Announced FDA Acceptance of KP484 IND
Slide 7: ADHD Prodrug Product Pipeline — Addressing Unmet Needs
ADHD Prodrug Product Pipeline — Addressing Unmet Needs KP415 — ADHD Product Candidate for Fast Onset and Longer Total Duration + Extended release product candidate + Prodrug of d-MPH co-formulated with IR d-MPH + Pivotal efficacy trial initiated; data expected by midyear 2018 + Recent, positive PK d
Slide 8: KemPharm Near-Term Product Candidates
KemPharm Near-Term Product Candidates Potential Product Development| —_ Next Fategony | candidate | ParentPrus Status Milestone lan Submission Methylphenidate PK + Efficacy KP415 (ER) Clinical Data Q12019 ADHD Methylphenidate - PK + Efficacy KP484 al Clinical zm 2019 __—SaS=e SSS SSS eS eet! Hydroco
Slide 9: KemPharm Expected Timelines
KemPharm Expected Timelines Product Event Date KP484 IND Filing rT an KP415 Initiate Pivotal Efficacy Study 2017—CY Apadaz™ FDA Approval 02/2318 v KP415/KP484 —_IV Human Abuse Liability (HAL) Data 2018 KP415 Pivotal Efficacy Study Results 2018 KP484 Initiate Pivotal Efficacy Study 2018 KP415/KP484 —
Slide 10: Pharm
K Pharm Q4 and FY 2017 Results